A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor (DSM421) with improved drug-like properties for treatment and prevention of malaria

The emergence of drug resistant malaria parasites continues to hamper efforts to control this lethal disease. Dihydroorotate dehydrogenase has recently been validated as a new target for the treatment of malaria and a selective inhibitor (DSM265) of the Plasmodium enzyme is currently in clinical dev...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:ACS Infect Dis
Autors principals: Phillips, Margaret A., White, Karen L., Kokkonda, Sreekanth, Deng, Xiaoyi, White, John, El Mazouni, Farah, Marsh, Kennan, Tomchick, Diana R., Manjalanagara, Krishne, Rudra, Kakali Rani, Wirjanata, Grennady, Noviyanti, Rintis, Price, Ric N, Marfurt, Jutta, Shackleford, David M., Chiu, Francis C.K., Campbell, Michael, Jimenez-Diaz, Maria Belen, Bazaga, Santiago Ferrer, Angulo-Barturen, Iñigo, Martinez, Maria Santos, Lafuente-Monasterio, Maria, Kaminsky, Werner, Silue, Kigbafori, Zeeman, Anne-Marie, Kocken, Clemens, Leroy, Didier, Blasco, Benjamin, Rossignol, Emilie, Rueckle, Thomas, Matthews, Dave, Burrows, Jeremy N., Waterson, David, Palmer, Michael J., Rathod, Pradipsinh K., Charman, Susan A.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5148661/
https://ncbi.nlm.nih.gov/pubmed/27641613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsinfecdis.6b00144
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars